---
schema_version: "secwatch.filing_event.v1"
accession: "0001999371-25-008651"
form_type: "8-K"
ticker: "TNXP"
cik: "0001430306"
company_name: "Tonix Pharmaceuticals Holding Corp."
filed_at: "2025-07-02T23:59:59+00:00"
generated_at: "2026-05-18T09:36:16.179985+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tonix announces preclinical data for TNX-1700 in gastric cancer models published in Cancer Cell

## Summary
- mTNX-1700 plus anti-PD-1 increased survival and decreased metastases in gastric cancer animal models vs anti-PD-1 alone.
- Treatment associated with activation of CD8+ T cells and limiting neutrophil-mediated immune evasion.
- Human version TNX-1700 (hTFF2-HSA) is in preclinical development for gastric and colorectal cancers.
- Collaboration with Columbia University's Medical School; paper titled 'A CXCR4 Partial Agonist, Improves Immunotherapy...'.
- Data support further development of TNX-1700 to overcome resistance to anti-PD-1 immunotherapy.

## SEC filing metadata
- accession: 0001999371-25-008651
- form_type: 8-K
- ticker: TNXP
- cik: 0001430306
- company_name: Tonix Pharmaceuticals Holding Corp.
- filed_at: 2025-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1430306/000199937125008651/0001999371-25-008651-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1430306/000199937125008651/tnxp-8k_070225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999371-25-008651
- JSON: https://secwatch.observer/filing/0001999371-25-008651.json
- Plain text: https://secwatch.observer/filing/0001999371-25-008651.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.